Transcription factor RUNX2 regulates epithelial‑mesenchymal transition and progression in renal cell carcinomas

Liu,Bitian; Liu,Junlong; Yu,Hongyuan; Wang,Changming; Kong,Chuize

doi:10.3892/or.2019.7428

Transcription factor RUNX2 regulates epithelial‑mesenchymal transition and progression in renal cell carcinomas

Authors:
- Bitian Liu
- Junlong Liu
- Hongyuan Yu
- Changming Wang
- Chuize Kong
View Affiliations

Affiliations: Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: December 12, 2019 https://doi.org/10.3892/or.2019.7428
Pages: 609-616

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is difficult to cure once it progresses and metastasizes. Runt‑related transcription factor 2 (RUNX2) is associated with the development or progression of various cancers, but its role in RCC remains unclear. The expression of RUNX2 is not only aberrantly increased in ccRCC, but also is increased with increasing tumor stage and pathological grade. The prognosis of patients with tumors expressing RUNX2, which was revealed to be highly expressed in survival analysis, was significantly worse. Gene set enrichment analysis revealed that the RUNX2‑mediated epithelial‑mesenchymal transition (EMT) pathway promoted tumor progression. In vitro, knockdown of RUNX2 inhibited the proliferation, migration, and invasion of RCC, with related proteins in the EMT pathway exhibiting corresponding changes. RUNX2 regulated EMT in RCC to promote tumor progression.

View Figures

View References

1	Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P: Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019. View Article : Google Scholar : PubMed/NCBI
2	Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
3	Liu Z, Yao X, Yan G, Xu Y, Yan J, Zou W and Wang G: Mediator MED23 cooperates with RUNX2 to drive osteoblast differentiation and bone development. Nat Commun. 7:111492016. View Article : Google Scholar : PubMed/NCBI
4	Ito Y, Bae SC and Chuang LS: The RUNX family: Developmental regulators in cancer. Nat Rev Cancer. 15:81–95. 2015. View Article : Google Scholar : PubMed/NCBI
5	Martin JW, Zielenska M, Stein GS, van Wijnen AJ and Squire JA: The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma. 2011:2827452011. View Article : Google Scholar : PubMed/NCBI
6	Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, et al: Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 29:811–821. 2010. View Article : Google Scholar : PubMed/NCBI
7	Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, Wang QS and Feng YM: ITGBL1 Is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFβ signaling pathway. Cancer Res. 75:3302–3313. 2015. View Article : Google Scholar : PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Johnson DE, O'Keefe RA and Grandis JR: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
10	Rani A and Murphy JJ: STAT5 in cancer and immunity. J Interferon Cytokine Res. 36:226–237. 2016. View Article : Google Scholar : PubMed/NCBI
11	Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S, et al: Identification of the tumour transition states occurring during EMT. Nature. 556:463–468. 2018. View Article : Google Scholar : PubMed/NCBI
12	Xiao J, Gong Y, Chen Y, Yu D, Wang X, Zhang X, Dou Y, Liu D, Cheng G, Lu S, et al: IL-6 promotes epithelial-to-mesenchymal transition of human peritoneal mesothelial cells possibly through the JAK2/STAT3 signaling pathway. Am J Physiol Renal Physiol. 313:F310–F318. 2017. View Article : Google Scholar : PubMed/NCBI
13	Shin S, Buel GR, Nagiec MJ, Han MJ, Roux PP, Blenis J and Yoon SO: ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation. Proc Natl Acad Sci USA. 116:2967–2976. 2019. View Article : Google Scholar : PubMed/NCBI
14	Nan X, Wang J, Liu HN, Wong STC and Zhao H: Epithelial-mesenchymal plasticity in organotropism metastasis and tumor immune escape. J Clin Med. 8:E7472019. View Article : Google Scholar : PubMed/NCBI
15	Dominguez C, David JM and Palena C: Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Semin Cancer Biol. 47:177–184. 2017. View Article : Google Scholar : PubMed/NCBI
16	Gupta A, Cao W and Chellaiah MA: Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis. Mol Cancer. 11:662012. View Article : Google Scholar : PubMed/NCBI
17	Lee YM, Kim JM, Lee HJ, Seong IO and Kim KH: Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas. Urol Oncol. 37:742–748. 2019. View Article : Google Scholar : PubMed/NCBI
18	Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY, Ryoo HM and Bae SC: Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol. 20:8783–8792. 2000. View Article : Google Scholar : PubMed/NCBI
19	Lebdai S, Verhoest G, Parikh H, Jacquet SF, Bensalah K, Chautard D, Rioux Leclercq N, Azzouzi AR and Bigot P: Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma. Urol Oncol. 33:69.e11–e68. 2015. View Article : Google Scholar